Literature DB >> 1635054

A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activity.

T J Tucker1, W C Lumma, L S Payne, J M Wai, S J de Solms, E A Giuliani, P L Darke, J C Heimbach, J A Zugay, W A Schleif.   

Abstract

A series of HIV-1 protease inhibitors containing a novel hydroxyethyl secondary amine transition state isostere has been synthesized. The compounds exhibit a strong preference for the (R) stereochemistry at the transition state hydroxyl group. Molecular modeling studies with the prototype compound 11 have provided important insights into the structural requirements for good inhibitor-active site binding interaction. N-Terminal extension of 11 into the P2-P3 region led to the discovery of 19, the most potent enzyme inhibitor in the series (IC50 = 5.4 nM). 19 was shown to have potent antiviral activity in cultured MT-4 human T-lymphoid cells. Comparison of analogs of 19 with analogs of 1 (Ro31-8959) demonstrates that considerably different structure-activity relationships exist between these two subclasses of hydroxyethylamine HIV-protease inhibitors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1635054     DOI: 10.1021/jm00092a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Structure-activity correlation study of HIV-1 inhibitors: electronic and molecular parameters.

Authors:  S Hannongbua; L Lawtrakul; J Limtrakul
Journal:  J Comput Aided Mol Des       Date:  1996-04       Impact factor: 3.686

2.  Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors.

Authors:  Pedro A Moura; John B Dame; David A Fidock
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

Review 3.  Viral proteases as targets for chemotherapeutic intervention.

Authors:  C U Hellen; E Wimmer
Journal:  Curr Opin Biotechnol       Date:  1992-12       Impact factor: 9.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.